

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/596,008	05/25/2006	Tomihisa Ohno	CONDA.00033	1688
22858 CARSTENS &	7590 08/12/200 CAHOON, LLP	EXAMINER		
PO BOX 8023	134		DOLLINGER, MICHAEL M	MICHAEL M
DALLAS, TX 75380			ART UNIT	PAPER NUMBER
			1796	
			MAIL DATE	DELIVERY MODE
			08/12/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)					
10/596,008	OHNO ET AL.					
Examiner	Art Unit					
MIKE DOLLINGER	1796					

	MIKE DOLLINGER	1796					
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress				
THE REPLY FILED 30 July 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of the application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:							
<ul> <li>a) The period for reply expires 3 months from the mailing date</li> </ul>							
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is Examiner Note: If box 1 is checked, check either box (a) or ( MONTHS OF THE FINAL REJECTION. See MPEP 706.07(	ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.				
Extensions of time may be obtained under 37 CFR 1.136(a). The date in have been filled is the date for purposes of determining the period value of 27 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office there may reduce any earmed patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	on which the petition under 37 CFR 1.1: ension and the corresponding amount of hortened statutory period for reply origithan three months after the mailing date	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as				
The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with the filed with th	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
<u>AMENDMENTS</u>							
3. The proposed amendment(s) filed after a final rejection, b  (a) They raise new issues that would require further cor  (b) They raise the issue of new matter (see NOTE belov  (c) They are not deemed to place the application in better	nsideration and/or search (see NOT w);	E below);					
appeal; and/or	ion form for appear by materially rec	raomig or omipmymig a	10 100000 101				
(d) ☐ They present additional claims without canceling a c	corresponding number of finally reje	ected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)).							
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (I	OL-324).				
Applicant's reply has overcome the following rejection(s):     Newly proposed or amended claim(s) would be all							
non-allowable claim(s). would be all	owabie ir submitted in a separate, t	imely filed amendmer	it canceling the				
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prov. The status of the claim(s) is (or will be) as follows:		be entered and an e	planation of				
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected: 1.3.4 and 6-9.							
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE							
The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).							
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appea	l and/or appellant fail:	to provide a				
<ol> <li>The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER</li> </ol>	n of the status of the claims after er	ntry is below or attach	ed.				
The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowan	ce because:				
12. Note the attached Information Disclosure Statement(s). ( 13. Other:	PTO/SB/08) Paper No(s).						
	/NI=41 NA NI-44 /						
	/Nathan M. Nutter/ Primary Examiner, Art U	nit 1796					

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Continuation of 11. does NOT place the application in condition for allowance because: Applicants argue that Hayakawa discloses a laundry list of compounds for each of the three elements which encompass the claimed components (a) and (b) and that Hayakawa does not disclose with sufficient specificity a lactone modified vinyl monomer with a hydroxyalkyl (meth) acrylate and a lactone polyol having three or more hydroxyl groups or a polyogaroliscone-modified hydroxyalkyl (meth) acrylate such that the average value of the caprolactone repetitive units its between 2 to 3 as in claim 1. (Examiner's Note: the average value of the caprolactone lengetitive units is actually between 1 to 3 in amended claim 1). This argument is not convincing. Component (b) of claim 1 of Hayakawa (columber 16 lines 11-33) specifically REGUIRES a polylactone modified hydroxyalkyl (meth) acrylate with 0-10 factone units, this component (b) also reads on a lactone polyol. Also, every example of the specification contains polymer which comprises a monomer of hydroxyethyl methagite modified with one unit of carpolactone with a hydroxy value that clearly indicates the claimed amount of hydroxy units requires in the lactone polyol. The foregoing is merely an example of the specificity of reductions of the value was and the scope of the reflection of record.